Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
Abstract
BACKGROUND
Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease (CKD), which can lead to cardiovascular diseases and the risk of fractures. Calcimimetics and active vitamin D analogs are the most frequently prescribed therapeutic drugs for treating this illness.
RESEARCH DESIGN AND METHODS
A decision-tree model was constructed from the perspective of the Chinese healthcare system, with a 1-year time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed.
RESULTS
Total annual costs were 20,771 yuan for cinacalcet, 34,350 yuan for paricalcitol, and 52,388 yuan for etelcalcetide. The ICER of etelcalcetide versus cinacalcet was 191,156.12 yuan per additional effective case, and 113,020.05 yuan versus paricalcitol. Cost-effectiveness acceptability curves indicated that cinacalcet was the optimal strategy when willingness-to-pay (WTP) was below 95,000 yuan per additional effective case; etelcalcetide became more cost-effective than paricalcitol when WTP exceeded 110,000 yuan per additional effective case, and became the optimal strategy among the three when WTP exceeded 190,000 yuan per additional effective case.
CONCLUSION
The optimal pharmacological strategy for SHPT depends on the WTP threshold. Cinacalcet is preferred at lower WTP levels, while etelcalcetide offers superior cost-effectiveness at higher WTP.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.